Clinical challenges in diagnosis and management of diabetic kidney disease

American Journal of Kidney Diseases

Volumn 63, Issue 2 SUPPL.2, 2014, Pages

  Stanton, Robert C ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

diabetes mellitus; Diabetic kidney disease (DKD); prevalence; public health; renal disease

Indexed keywords

ANGIOTENSIN II; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIPID; RENIN INHIBITOR;

ARTICLE; BLOOD PRESSURE; DIABETES MELLITUS; DIABETIC KIDNEY DISEASE; DISEASE COURSE; DRUG MECHANISM; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; PATIENT CARE; PRIMARY PREVENTION; PROTEIN INTAKE; PROTEIN RESTRICTION; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOKING CESSATION; WEIGHT REDUCTION;

DIABETES MELLITUS; DIABETIC KIDNEY DISEASE (DKD); PREVALENCE; PUBLIC HEALTH; RENAL DISEASE;

DIABETIC NEPHROPATHIES; HEALTH CARE COSTS; HUMANS; PREVALENCE; PUBLIC HEALTH;

EID: 84892949060     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.10.050     Document Type: Article

References (134)

1. A.J. Collins, R.N. Foley, and C. Herzog et al. US Renal Data System 2012 annual data report Am J Kidney Dis 61 1 suppl 1 2013 e1 e480
2. J.L. Gross, M.J. de Azevedo, S.P. Silveiro, L.H. Canani, M.L. Caramori, and T. Zelmanovitz Diabetic nephropathy: diagnosis, prevention, and treatment Diabetes Care 28 1 2005 164 176 (Pubitemid 40095801)
3. H.J. Heerspink, and D. de Zeeuw The kidney in type 2 diabetes therapy Rev Diabet Stud 8 3 2011 392 402
4. National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 60 5 2012 850 886
5. P. Ruggenenti, P. Cravedi, and G. Remuzzi The RAAS in the pathogenesis and treatment of diabetic nephropathy Nat Rev Nephrol 6 6 2010 319 330
6. Centers for Disease Control and Prevention. Diabetes report card 2012: national and state profile of diabetes and its complications. http://www.cdc.gov/diabetes/pubs/reportcard.htm. Accessed April 3, 2013.
7. M. Wilchesky, R.M. Tamblyn, and A. Huang Validation of diagnostic codes within medical services claims J Clin Epidemiol 57 2 2004 131 141 (Pubitemid 38668607)
8. A. Sessa, M. Meroni, G. Battini, M. Vaccari, F. Giordano, and L. Torri Tarelli IgA nephropathy complicating diabetic glomerulosclerosis Nephron 80 4 1998 488 489 (Pubitemid 28554705)
9. H. Bi, N. Chen, G. Ling, S. Yuan, G. Huang, and R. Liu Nondiabetic renal disease in type 2 diabetic patients: a review of our experience in 220 cases Ren Fail 33 1 2011 26 30
10. T.T. Pham, J.J. Sim, D.A. Kujubu, I.L. Liu, and V.A. Kumar Prevalence of nondiabetic renal disease in diabetic patients Am J Nephrol 27 3 2007 322 328 (Pubitemid 47164683)
11. W.M. Michels, D.C. Grootendorst, M. Verduijn, E.G. Elliott, F.W. Dekker, and R.T. Krediet Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size Clin J Am Soc Nephrol 5 6 2010 1003 1009
12. M. Afkarian, M.C. Sachs, and B. Kestenbaum et al. Kidney disease and increased mortality risk in type 2 diabetes J Am Soc Nephrol 24 2 2013 302 308
13. E.B. Jude, S.G. Anderson, and J.K. Cruickshank et al. Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes QJM 95 6 2002 371 377 (Pubitemid 34649673)
14. P. Muntner, C.B. Bowling, and L. Gao et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality Clin J Am Soc Nephrol 6 9 2011 2200 2207
15. T. Ninomiya, V. Perkovic, and B.E. de Galan et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes J Am Soc Nephrol 20 8 2009 1813 1821
16. C. Couchoud, and E. Villar End-stage renal disease epidemic in diabetics: is there light at the end of the tunnel? Nephrol Dial Transplant 28 5 2013 1073 1076
17. M.E. Pavkov, W.C. Knowler, R.L. Hanson, and R.G. Nelson Diabetic nephropathy in American Indians, with a special emphasis on the Pima Indians Curr Diab Rep 8 6 2008 486 493
18. S. Debnath, F. Thameem, and T. Alves et al. Diabetic nephropathy among Mexican Americans Clin Nephrol 77 4 2012 332 344
19. A.J. Collins, R.N. Foley, D.T. Gilbertson, and S.C. Chen The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis Clin J Am Soc Nephrol 4 suppl 1 2009 S5 S11
20. E.D. Crook, and S.R. Patel Diabetic nephropathy in African-American patients Curr Diab Rep 4 6 2004 455 461 (Pubitemid 40104222)
21. R.L. Hanson, M.P. Millis, and N.J. Young et al. ELMO1 variants and susceptibility to diabetic nephropathy in American Indians Mol Genet Metab 101 4 2010 383 390
22. C.W. McDonough, M.A. Bostrom, and L. Lu et al. Genetic analysis of diabetic nephropathy on chromosome 18 in African Americans: linkage analysis and dense SNP mapping Hum Genet 126 6 2009 805 817
23. C.W. McDonough, N.D. Palmer, and P.J. Hicks et al. A genome-wide association study for diabetic nephropathy genes in African Americans Kidney Int 79 5 2011 563 572
24. E. Ritz, and S.R. Orth Nephropathy in patients with type 2 diabetes mellitus N Engl J Med 341 15 1999 1127 1133 (Pubitemid 29466226)
25. P. Finne, A. Reunanen, S. Stenman, P.H. Groop, and C. Gronhagen-Riska Incidence of end-stage renal disease in patients with type 1 diabetes JAMA 294 14 2005 1782 1787 (Pubitemid 41434624)
26. A. Rodriguez-Poncelas, J. Garre-Olmo, and J. Franch-Nadal et al. Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 Study BMC Nephrol 14 2013 46
27. J. Lv, D. Xu, and V. Perkovic et al. Corticosteroid therapy in IgA nephropathy J Am Soc Nephrol 23 6 2012 1108 1116
28. W.G. Couser, G. Remuzzi, S. Mendis, and M. Tonelli The contribution of chronic kidney disease to the global burden of major noncommunicable diseases Kidney Int 80 12 2011 1258 1270
29. Q.L. Zhang, and D. Rothenbacher Prevalence of chronic kidney disease in population-based studies: systematic review BMC Public Health 8 2008 117
30. K. Kiryluk, Y. Li, and S. Sanna-Cherchi et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis PLoS Genet 8 6 2012 e1002765
31. Y. Cao, W. Li, G. Yang, Y. Liu, and X. Li Diabetes and hypertension have become leading causes of CKD in Chinese elderly patients: a comparison between 1990-1991 and 2009-2010 Int Urol Nephrol 44 4 2012 1269 1276
32. G. Wolf, N. Muller, A. Mandecka, and U.A. Muller Association of diabetic retinopathy and renal function in patients with types 1 and 2 diabetes mellitus Clin Nephrol 68 2 2007 81 86 (Pubitemid 47243952)
33. M.L. Caramori, P. Fioretto, and M. Mauer Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions Diabetes 52 4 2003 1036 1040 (Pubitemid 36384275)
34. J.M. Steinke, M. Mauer International Diabetic Nephropathy Study Group Lessons learned from studies of the natural history of diabetic nephropathy in young type 1 diabetic patients Pediatr Endocrinol Rev 5 suppl 4 2008 958 963
35. J.M. Steinke, A.R. Sinaiko, and M.S. Kramer et al. The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients Diabetes 54 7 2005 2164 2171 (Pubitemid 40911280)
36. B.A. Perkins, L.H. Ficociello, K.H. Silva, D.M. Finkelstein, J.H. Warram, and A.S. Krolewski Regression of microalbuminuria in type 1 diabetes N Engl J Med 348 23 2003 2285 2293 (Pubitemid 36638102)
37. B.A. Perkins, L.H. Ficociello, and B.E. Ostrander et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes J Am Soc Nephrol 18 4 2007 1353 1361 (Pubitemid 46536923)
38. J.P. Dwyer, H.H. Parving, L.G. Hunsicker, M. Ravid, G. Remuzzi, and J.B. Lewis Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND Study Cardiorenal Med 2 1 2012 1 10
39. G. Mazzucco, T. Bertani, M. Fortunato, F. Fop, and G. Monga The prognostic value of renal biopsy in type 2 diabetes mellitus patients affected by diabetic glomerulosclerosis J Nephrol 18 6 2005 696 702 (Pubitemid 43085436)
40. B. Najafian, and M. Mauer Progression of diabetic nephropathy in type 1 diabetic patients Diabetes Res Clin Pract 83 1 2009 1 8
41. R.E. Gilbert, and M.E. Cooper The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56 5 1999 1627 1637 (Pubitemid 29518163)
42. K. Kanasaki, G. Taduri, and D. Koya Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis Front Endocrinol (Lausanne) 4 2013 7
43. D.K. Singh, and K. Farrington The tubulointerstitium in early diabetic nephropahty: prime target or innocent bystander? Int J Diabetes Dev Countries 30 4 2010 185 190
44. T.W. Tervaert, A.L. Mooyaart, and K. Amann et al. Pathologic classification of diabetic nephropathy J Am Soc Nephrol 21 4 2010 556 563
45. M.J. Soler, M. Riera, and D. Batlle New experimental models of diabetic nephropathy in mice models of type 2 diabetes: efforts to replicate human nephropathy Exp Diabetes Res 2012 2012 616313
46. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus N Engl J Med 329 14 1993 977 986
47. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 9131 1998 837 853
48. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy N Engl J Med 342 6 2000 381 389
49. Group DER I.H. de Boer, and W. Sun et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes N Engl J Med 365 25 2011 2366 2376
50. Y. Ohkubo, H. Kishikawa, and E. Araki et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study Diabetes Res Clin Pract 28 2 1995 103 117
51. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Research Group Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) Study JAMA 290 16 2003 2159 2167
52. P. Hovind, P. Rossing, L. Tarnow, U.M. Smidt, and H.H. Parving Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively Kidney Int 60 1 2001 277 283 (Pubitemid 32587565)
53. A.N. Lasaridis, and P.A. Sarafidis Diabetic nephropathy and antihypertensive treatment: what are the lessons from clinical trials? Am J Hypertens 16 8 2003 689 697 (Pubitemid 36900594)
54. J.B. Lewis, T. Berl, R.P. Bain, R.D. Rohde, and E.J. Lewis Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group Am J Kidney Dis 34 5 1999 809 817 (Pubitemid 29521695)
55. R.W. Schrier, R.O. Estacio, A. Esler, and P. Mehler Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes Kidney Int 61 3 2002 1086 1097 (Pubitemid 34175478)
56. V.A. Chakkarwar Smoking in diabetic nephropathy: sparks in the fuel tank? World J Diabetes 3 12 2012 186 195
57. S. Tonstad Cigarette smoking, smoking cessation, and diabetes Diabetes Res Clin Pract 85 1 2009 4 13
58. G.L. Bakris Slowing nephropathy progression: focus on proteinuria reduction Clin J Am Soc Nephrol 3 suppl 1 2008 S3 S10
59. D. de Zeeuw, G. Remuzzi, and H.H. Parving et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL Kidney Int 65 6 2004 2309 2320 (Pubitemid 38670018)
60. G. Eknoyan Obesity, diabetes, and chronic kidney disease Curr Diab Rep 7 6 2007 449 453 (Pubitemid 350284976)
61. M. Praga, and E. Morales Obesity, proteinuria and progression of renal failure Curr Opin Nephrol Hypertens 15 5 2006 481 486
62. M.E. Williams, and R. Garg Glycemic management in ESRD and earlier stages of CKD Am J Kidney Dis 63 2 suppl 2 2014 S22 S38
63. G. Reboldi, G. Gentile, F. Angeli, and P. Verdecchia Optimal therapy in hypertensive subjects with diabetes mellitus Curr Atheroscler Rep 13 2 2011 176 185
64. P.N. Van Buren, and R. Toto Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management Adv Chronic Kidney Dis 18 1 2011 28 41
65. R.O. Estacio, J.R. Coll, Z.V. Tran, and R.W. Schrier Effect of intensive blood pressure control with valsartan on urinary albumin excretion in normotensive patients with type 2 diabetes Am J Hypertens 19 12 2006 1241 1248 (Pubitemid 44856249)
66. Clinical Practice Guidelines Diabetes Care 36 suppl 1 2013 S29 S31
67. Accord Study Group W.C. Cushman, G.W. Evans, and R.P. Byington et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus N Engl J Med 362 17 2010 1575 1585
68. R.M. Cooper-DeHoff, Y. Gong, and E.M. Handberg et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease JAMA 304 1 2010 61 68
69. G.L. Bakris, M.R. Weir, and S. Shanifar et al. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL Study Arch Intern Med 163 13 2003 1555 1565 (Pubitemid 36835100)
70. G.L. Bakris, M. Williams, and L. Dworkin et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group Am J Kidney Dis 36 3 2000 646 661
71. T. Berl, L.G. Hunsicker, and J.B. Lewis et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial J Am Soc Nephrol 16 7 2005 2170 2179 (Pubitemid 41716450)
72. L. Gnudi, and D. Goldsmith Renin angiotensin aldosterone system (RAAS) inhibitors in the prevention of early renal disease in diabetes F1000 Med Rep 2010 2
73. K.J. Schjoedt The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone Dan Med Bull 58 4 2011 B4265
74. M.W. Taal, and B.M. Brenner Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists Kidney Int 57 5 2000 1803 1817 (Pubitemid 30252273)
75. F.A. Holtkamp, D. de Zeeuw, and M.C. Thomas et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function Kidney Int 80 3 2011 282 287
76. J. Lv, V. Perkovic, C.V. Foote, M.E. Craig, J.C. Craig, and G.F. Strippoli Antihypertensive agents for preventing diabetic kidney disease Cochrane Database Syst Rev 12 2012 CD004136
77. M. Mauer, B. Zinman, and R. Gardiner et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes N Engl J Med 361 1 2009 40 51
78. R. Bilous, N. Chaturvedi, and A.K. Sjolie et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials Ann Intern Med 151 1 2009 11 20 W13-W14
79. G. Remuzzi, M. Macia, and P. Ruggenenti Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT Study J Am Soc Nephrol 17 4 suppl 2 2006 S90 S97
80. L.A. Hebert, M.E. Falkenhain, N.S. Nahman Jr., F.G. Cosio, and T.M. O'Dorisio Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy Am J Nephrol 19 1 1999 1 6 (Pubitemid 29139863)
81. C.E. Mogensen, S. Neldam, and I. Tikkanen et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study BMJ 321 7274 2000 1440 1444
82. A. Erman, S. Veksler, U. Gafter, G. Boner, C. Wittenberg, and D.J. van Dijk Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat J Renin Angiotensin Aldosterone Syst 5 3 2004 146 151 (Pubitemid 39406724)
83. H. Abe, S. Minatoguchi, and H. Ohashi et al. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy Hypertens Res 30 10 2007 929 935 (Pubitemid 350120970)
84. D.L. Jennings, J.S. Kalus, C.I. Coleman, C. Manierski, and J. Yee Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis Diabet Med 24 5 2007 486 493 (Pubitemid 46669317)
85. J.T. Pham, B.P. Schmitt, and D.J. Leehey Effects of dual blockade of the renin-angiotensin system in diabetic kidney disease: a systematic review and meta-analysis J Nephrol Ther suppl 2 2012 1 8
86. ONTARGET Investigators S. Yusuf, K.K. Teo, and J. Pogue et al. Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 15 2008 1547 1559 (Pubitemid 351522739)
87. S.W. Tobe, C.M. Clase, and P. Gao et al. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies Circulation 123 10 2011 1098 1107
88. G. Fernandez Juarez, J. Luno, and V. Barrio et al. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial Am J Kidney Dis 61 2 2013 211 218
89. P. Cravedi, P. Ruggenenti, and G. Remuzzi Proteinuria should be used as a surrogate in CKD Nat Rev Nephrol 8 5 2012 301 306
90. G.L. Bakris Dual RAAS blockade is desirable in kidney disease: con Kidney Int 78 6 2010 546 549
91. M.R. Lattanzio, and M.R. Weir Have we fallen off target with concerns surrounding dual RAAS blockade? Kidney Int 78 6 2010 539 545
92. L.F. Fried, N. Emanuele, and J.H. Zhang et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 20 2013 1892 1903
93. Remuzzi G. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). http://clinicaltrials.gov/show/NCT00494715. Accessed August 15, 2013.
94. P. Ruggenenti, A. Perna, G. Remuzzi Gruppo Italiano di Studi Epidemiologici in Nefrologia ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy J Am Soc Nephrol 12 12 2001 2832 2837 (Pubitemid 33115432)
95. B.M. Brenner, T.W. Meyer, and T.H. Hostetter Dietary protein intake and the progressive nature of kidney disease: the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease N Engl J Med 307 11 1982 652 659 (Pubitemid 12049914)
96. F. Angeli, G. Reboldi, and G. Mazzotta et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions Curr Drug Saf 7 1 2012 76 85
97. H.H. Parving, F. Persson, J.B. Lewis, E.J. Lewis, N.K. Hollenberg ALTITUDE Study Investigators Aliskiren combined with losartan in type 2 diabetes and nephropathy N Engl J Med 358 23 2008 2433 2446 (Pubitemid 351793017)
98. H.H. Parving, B.M. Brenner, and J.J. McMurray et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design Nephrol Dial Transplant 24 5 2009 1663 1671
99. H.H. Parving, B.M. Brenner, and J.J. McMurray et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes N Engl J Med 367 23 2012 2204 2213
100. M. Briet, and E.L. Schiffrin Aldosterone: effects on the kidney and cardiovascular system Nat Rev Nephrol 6 5 2010 261 273
101. N.J. Brown Aldosterone and end-organ damage Curr Opin Nephrol Hypertens 14 3 2005 235 241 (Pubitemid 40685635)
102. C. Catena, G. Colussi, G. Brosolo, L. Iogna-Prat, and L.A. Sechi Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new Am J Cardiovasc Dis 2 1 2012 50 57
103. C. Catena, G. Colussi, L. Marzano, and L.A. Sechi Aldosterone and the heart: from basic research to clinical evidence Horm Metab Res 44 3 2012 181 187
104. S.D. Navaneethan, S.U. Nigwekar, A.R. Sehgal, and G.F. Strippoli Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis Clin J Am Soc Nephrol 4 3 2009 542 551
105. Y.S. Kang, and D.R. Cha Aldosterone and diabetic kidney disease Curr Diab Rep 9 6 2009 453 459
106. G.L. Bakris, J.B. Copley, N. Vicknair, R. Sadler, and S. Leurgans Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy Kidney Int 50 5 1996 1641 1650 (Pubitemid 26364270)
107. G.L. Bakris, A. Mangrum, J.B. Copley, N. Vicknair, and R. Sadler Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans Hypertension 29 3 1997 744 750 (Pubitemid 27097979)
108. G.L. Bakris, M.R. Weir, V. DeQuattro, and F.G. McMahon Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy Kidney Int 54 4 1998 1283 1289 (Pubitemid 28449916)
109. M. Perez-Maraver, M.J. Carrera, and T. Micalo et al. Renoprotective effect of diltiazem in hypertensive type 2 diabetic patients with persistent microalbuminuria despite ACE inhibitor treatment Diabetes Res Clin Pract 70 1 2005 13 19 (Pubitemid 41207642)
110. R.D. Toto, M. Tian, K. Fakouhi, A. Champion, and P. Bacher Effects of calcium channel blockers on proteinuria in patients with diabetic nephropathy J Clin Hypertens (Greenwich) 10 10 2008 761 769
111. S. Badri, S. Dashti-Khavidaki, M. Lessan-Pezeshki, and M. Abdollahi A review of the potential benefits of pentoxifylline in diabetic and non-diabetic proteinuria J Pharm Pharm Sci 14 1 2011 128 137
112. A. Ghorbani, B. Omidvar, S.S. Beladi-Mousavi, E. Lak, and S. Vaziri The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial Nefrologia 32 6 2012 790 796
113. J. Roozbeh, M.A. Banihashemi, and M. Ghezlou et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy Ren Fail 32 2 2010 172 178
114. T.H. Hostetter, J.L. Olson, H.G. Rennke, M.A. Venkatachalam, and B.M. Brenner Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation Am J Physiol 241 1 1981 F85 F93
115. R. Zatz, T.W. Meyer, H.G. Rennke, and B.M. Brenner Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy Proc Natl Acad Sci U S A 82 17 1985 5963 5967 (Pubitemid 16218883)
116. S. Klahr, A.S. Levey, and G.J. Beck et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group N Engl J Med 330 13 1994 877 884 (Pubitemid 24094966)
117. A.S. Levey, T. Greene, and G.J. Beck et al. Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD Study shown? Modification of Diet in Renal Disease Study Group J Am Soc Nephrol 10 11 1999 2426 2439 (Pubitemid 29501478)
118. L. Robertson, N. Waugh, and A. Robertson Protein restriction for diabetic renal disease Cochrane Database Syst Rev 17 4 2007 CD002181
119. V. Bellizzi, B.R. Di Iorio, and L. De Nicola et al. Very low protein diet supplemented with ketoanalogs improves blood pressure control in chronic kidney disease Kidney Int 71 3 2007 245 251 (Pubitemid 46160925)
120. D. Fouque, and M. Aparicio Eleven reasons to control the protein intake of patients with chronic kidney disease Nat Clin Pract Nephrol 3 7 2007 383 392 (Pubitemid 46987805)
121. S.R. Orth, H. Ogata, and E. Ritz Smoking and the kidney Nephrol Dial Transplant 15 10 2000 1509 1511
122. P.T. Sawicki, U. Didjurgeit, I. Muhlhauser, R. Bender, L. Heinemann, and M. Berger Smoking is associated with progression of diabetic nephropathy Diabetes Care 17 2 1994 126 131 (Pubitemid 24035307)
123. F. Bonnet, and M.E. Cooper Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies Diabetes Metab 26 4 2000 254 264
124. H. Gin, V. Rigalleau, and M. Aparicio Lipids, protein intake, and diabetic nephropathy Diabetes Metab 26 suppl 4 2000 45 53 (Pubitemid 30618356)
125. R.F. Rosario, and S. Prabhakar Lipids and diabetic nephropathy Curr Diab Rep 6 6 2006 455 462 (Pubitemid 44896405)
126. O. Stojceva-Taneva, M. Polenakovic, R. Grozdanovski, and A. Sikole Lipids, protein intake, and progression of diabetic nephropathy Nephrol Dial Transplant 16 suppl 6 2001 90 91 (Pubitemid 32970525)
127. R. Trevisan, A.R. Dodesini, and G. Lepore Lipids and renal disease J Am Soc Nephrol 17 4 suppl 2 2006 S145 S147
128. T.M. Davis, R. Ting, and J.D. Best et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Diabetologia 54 2 2011 280 290
129. R.D. Ting, A.C. Keech, and P.L. Drury et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study Diabetes Care 35 2 2012 218 225
130. D.E. Bonds, T.E. Craven, and J. Buse et al. Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience Diabetologia 55 6 2012 1641 1650
131. P. Gaede, H. Lund-Andersen, H.H. Parving, and O. Pedersen Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 6 2008 580 591 (Pubitemid 351214285)
132. C. Maric, and J.E. Hall Obesity, metabolic syndrome and diabetic nephropathy Contrib Nephrol 170 2011 28 35
133. G. Perez, N. Devaud, A. Escalona, and P. Downey Resolution of early stage diabetic nephropathy in an obese diabetic patient after gastric bypass Obes Surg 16 10 2006 1388 1391 (Pubitemid 44671816)
134. K. Amann, and K. Benz Structural renal changes in obesity and diabetes Semin Nephrol 33 1 2013 23 33